Grupo Bruluart

What Grupo Bruluart does

Grupo Bruluart is a privately-held Mexican pharmaceutical group composed of 100% Mexican companies operating across generic drug manufacturing, distribution, and pharmacy retail. The group is structured around manufacturing subsidiaries I.M. Bruluart, S.A. and Bruluagsa S.A. de C.V., distribution subsidiary Brudifarma, and pharmacy retail chain Farmacias GI — providing vertical integration from formulation through to consumer access. Its portfolio contains 80+ branded generic pharmaceutical products spanning 9 therapeutic categories: contraceptives, anti-inflammatory, respiratory, antibiotics, metabolic (including diabetes), vitamins, gastrointestinal, antihypertensives, and antihistamines, delivered in tablets, capsules, syrups, suspensions, and injectable formulations.

The company operates a formal pharmacovigilance program with adverse-event reporting infrastructure across its manufacturing subsidiaries, signaling COFEPRIS-grade regulatory compliance. Production covers a wide range of established molecules including omeprazole, metformin, amoxicillin, ciprofloxacin, paracetamol, dexamethasone, and hormonal contraceptives such as MESBRU (algestone/estradiol) and MESLART (norethisterone/estradiol). Distribution runs through the owned Farmacias GI retail chain and broader Mexican pharmacy channels, with marketing executed via a health education blog and social media presence on Facebook, Twitter, and LinkedIn.

The company is headquartered in Estado de México, operates with a headcount band of 1,001-5,000 employees, and serves the Mexican population exclusively with no disclosed international expansion. Its stated mission is to manufacture and commercialize high-quality pharmaceutical products at accessible prices, positioning around affordability of generic medications across multiple therapeutic areas. No revenue, funding rounds, M&A activity, AI capabilities, or external investors are disclosed in available sources.

Name

Grupo Bruluart

Legal name

Grupo Bruluart

Website

https://grupobruluart.com

Company type

Private

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Grupo Bruluart is a privately-held Mexican pharmaceutical group that manufactures and distributes 80+ branded generic medications across 9 therapeutic categories through manufacturing subsidiaries I.M. Bruluart and Bruluagsa, distribution arm Brudifarma, and the owned Farmacias GI pharmacy retail chain serving the Mexican population.

Ownership category

akta.pro rank

Product category

Generic Pharmaceutical Manufacturing

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Pharmacies and Drug Retailers (456110), Pharmacies and Drug Retailers (45611)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Retail-Drug Stores And Proprietary Stores (5912)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Gastroenterology Specialty Pharmaceuticals (HLAIACAE)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Antibiotic medications
• Anti-inflammatory drugs
• Contraceptive products

Headquarters

HQ city

Estado De México

HQ country

Mexico

HQ region

Latin America

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Distribution channels1 record

Marketing channels2 records

Core offering

Grupo Bruluart is a 100% Mexican pharmaceutical group that manufactures and commercializes generic medications across nine therapeutic categories: contraceptives, anti-inflammatory, respiratory, antibiotics, metabolism, vitamins, gastrointestinal, antihypertensives, and antihistamines. The portfolio includes over 80 branded generic products available in multiple formats (tablets, capsules, syrups, suspensions, injectables), distributed through its owned pharmacy chain Farmacias GI and partner pharmacies across Mexico.

Product overview

Grupo Bruluart is a 100% Mexican pharmaceutical group composed of subsidiary companies (I.M. Bruluart, Bruluagsa, and Brudifarma) dedicated to manufacturing and commercializing high-quality generic medications. The company operates across nine therapeutic lines: Contraceptives (Anticonceptivos Hormonales - MESBRU, MESLART), Anti-inflammatory (Anti-inflamatorios), Respiratory (Vías Respiratorias - ADRIBEL, OXOLVAN, BRUSAL), Antibiotics (Antibióticos - BRUBIOL, CLAVIPEN, DIMOPEN), Metabolism (Metabolismo - DINORAX, DINORAX C), Vitamins (Vitamínicos - TRIBEDOCE, TILARMIN), Gastrointestinal (Gastrointestinales - LOZARBRU, AGRIXAL), Antihypertensive (Anti-hipertensivos - BRUCAP, EKARIL, NIPRESOL), and Antihistamines (Anti-histamínicos - BLOTAMIN, LORIMOX). Their portfolio includes over 80 branded generic pharmaceutical products including tablets, capsules, syrups, suspensions, and injectable solutions distributed through partner pharmacy chains including Farmacias GI.

Differentiator

Problem solved

Functional benefit

Products and services

• Contraceptives (Anticonceptivos Hormonales) Line of monthly injectable hormonal contraceptive products for pregnancy prevention, distributed through Mexican pharmacies.
• Anti-inflammatory medications (Anti-inflamatorios) Range of NSAIDs, analgesics, and corticosteroid formulations for pain, inflammation, and fever treatment in tablets, injectables, and suspensions.
• Respiratory medications (Vías Respiratorias) Bronchodilator, expectorant, antitussive, and mucolytic formulations in syrups, tablets, and solutions for asthma, cough, and respiratory conditions.
• Antibiotics (Antibióticos) Broad-spectrum antibiotic portfolio including penicillins, cephalosporins, aminoglycosides, fluoroquinolones, tetracyclines, antifungals, and sulfonamides for bacterial infections.
• Metabolism medications (Metabolismo) Oral antidiabetic agents (sulfonylureas, biguanides, combinations) and lipid-lowering medications for type 2 diabetes and hyperlipidemia management.
• Vitamin supplements (Vitamínicos) Vitamin and mineral supplement solutions including single vitamins (A, D, folic acid), B-complex formulations, and combination multivitamin injections for nutritional support.
• Gastrointestinal medications (Gastrointestinales)

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core.

• Farmacias GIcoreChannel Partner/ Reseller/ DistributorFarmacias GI is a pharmacy chain that operates as part of Grupo Bruluart, distributing the group's generic pharmaceutical products directly to consumers in Mexico. This subsidiary relationship enables the company to have direct retail presence in the Mexican pharmaceutical market.
• BrudifarmacoreChannel Partner/ Reseller/ DistributorBrudifarma is a subsidiary company within the Grupo Bruluart conglomerate, contributing to the group's pharmaceutical distribution and commercialization activities in Mexico.
• I.M. Bruluart, S.A.coreOthers
• Bruluagsa S.A. de C.V.coreOthers

Recent moves5 records

Expansion highlights4 records

Direct peers

• Genomma Laboratories Internacional: Mexico's largest publicly listed pharmaceutical company focused on OTC and generic pharmaceuticals sold primarily through retail pharmacy chains. Directly comparable in therapeutic categories, Mexican market focus, and retail-channel distribution model.
• Laboratorios Liomont: Privately held Mexican pharmaceutical manufacturer producing branded generics and specialty pharma across multiple therapeutic areas. Comparable as a Mexican-domestic generic manufacturer with a similar product breadth.
• Laboratorios Sanfer: Mexican pharmaceutical group with branded generics and OTC products distributed across therapeutic categories including antibiotics, anti-inflammatories, and chronic disease treatments. Comparable product mix and Mexican-market focus.
• Apotex: Canadian generic pharmaceutical manufacturer producing a broad portfolio of small-molecule generics across therapeutic categories. Comparable business model as a multi-therapeutic generic manufacturer; operates across the Americas.
• Eurofarma Laboratórios: Brazilian pharmaceutical company with a large branded generics and OTC portfolio serving Latin American markets. Comparable multi-therapeutic generic manufacturer in an emerging Latin American market with similar distribution models.
• EMS Farmacêutica: Brazil's largest pharmaceutical company by units sold, focused on branded generics across multiple therapeutic categories. Comparable in scale, product breadth, and Latin American emerging-market distribution model.
• Aché Laboratórios Farmacêuticos: Brazilian pharmaceutical company with a branded generics and prescription portfolio distributed across therapeutic areas. Comparable as a vertically integrated Latin American generics manufacturer with broad product coverage.
• Laboratorios Chinoin: Mexican pharmaceutical manufacturer producing branded generics and OTC products distributed through retail pharmacies in Mexico. Comparable product mix and Mexican-market channel relationships.

Broad incumbents

• Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with extensive product breadth across all major therapeutic categories. Functions as a broad incumbent in the global generics space rather than a direct Mexican-market competitor.
• Sandoz (Novartis): Global generic and biosimilar pharmaceutical company within Novartis, offering broad small-molecule generic coverage. A broad incumbent rather than a direct competitor in the Mexican generics retail channel.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/grupobruluart
• Facebookfacebook.com/GrupoBruluart
• LinkedInlinkedin.com/company/grupo-bruluart

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Grupo Bruluart